The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Partnership

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ('ANGLE' or 'the Company') 20 year strategic partnership with The University of Reading ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce that it hassigned a 20 year strategic partnership with The University of Reading ('University'). Under the terms of the agreement, ANGLE has the exclusive right of first refusalto invest in all University intellectual property (IP) that is commercialised.Where ANGLE exercises this right, it will invest under a set formula obtainingan equity stake of 60% in each spin-out company for an investment of up to £0.5million. ANGLE will drive development of these ventures utilising itsproprietary Progeny(R) process. Additionally, ANGLE will receive a 15% share in all commercial returns fromUniversity IP, both licensing and spin-out, in which ANGLE does not invest. Inexchange, ANGLE will provide consultancy support to the University on IPcommercialisation. In total, ANGLE expects to invest at least £3.0 million over the first fiveyears of the agreement and expects that this will be funded from existingresources. The University has income of more than £150 million per annum and over 1,000academic staff. The most recent government Research Assessment Exercise ratedtwenty of its departments as 5 or 5*, denoting international excellence inresearch activity. This excellence is found in areas as diverse as climatephysics, fluid dynamics and food biosciences, the latter of which is ideallyplaced as the global market for functional foods grows towards an estimated $95billion per annum by 2010. In addition, the University's Instrumentation &Signal Processing Research Group and Cybernetic Intelligence Research Group bothpossess not only high international reputations but also strong histories ofproducing groundbreaking, commercial technologies. ANGLE is already workingwith the University to evaluate opportunities arising from these and otherareas. The University has a long tradition of being at the forefront of commercialactivities, as the first British university to integrate an industrial R&D groupon its campus; the first university to win the Queen's Award for ExportAchievement; the host to the UK's leading Knowledge Transfer Partnership (KTP)Centre; the provider of one of the largest credit bearing entrepreneurshipteaching programmes in the UK; and the home of InnovationWorks@Reading, afacility for creative problem solving unique in the South East. Existingspin-out companies include Whitfield Solar, a developer of low-cost solar powersolutions that has recently joined the Carbon Trust's Incubator managed byANGLE. ANGLE's Director of New Ventures, Stephen Bence, said: "The University of Reading is a top rated research University with strength indepth through its technology base. We are delighted to have the opportunity towork with the University to commercialise its intellectual property over anextended period of time and look forward to some early successes." ANGLE's Group Chief Executive, Andrew Newland, added: "We are delighted to sign The University of Reading as ANGLE's first UKstrategic partnership. Establishing long-term relationships with owners ofimpressive intellectual property represents a new phase in ANGLE's strategicdevelopment. This ground-breaking deal is the first of a number of such dealsthat we expect to be able to announce over the next 18 months." David Savage, Director of Finance and Corporate Services at The University ofReading, said: "We have been approached by a number of IP commercialisation groups interestedin investing in the University's intellectual property but ANGLE offered aunique combination of consultancy expertise in identifying opportunities andproactive management of their development. We are confident that this strategicpartnership will deliver a step change in technology transfer from TheUniversity of Reading for the benefit of the UK economy." The University's Technology Transfer Manager, Sue O'Hare, added: "ANGLE's track record of successful spin-out companies and network ofexperienced and well-connected people are impressive. We are very excited by theopportunity to work closely with them to realise the potential of theUniversity's intellectual property and to maintain and develop the University'srecord of being at the leading edge." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures The University of Reading +44 118 935 7198Sue O'Hare, Technology Transfer Manager Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About The University of Reading The University of Reading is one of the top 20 research-intensive universitiesin the UK, with a world-wide reputation in the areas of environmentaltechnologies, agriculture, food biosciences, information and communicationstechnologies, construction management, and financial markets. The University iscommitted to achieving excellence in research, teaching and enterprise and totranslating its excellence into a major contribution to culture, economicwell-being and the quality of life. For more information, visit www.reading.ac.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.